These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 17874331

  • 1. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
    Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R, Coleman RE.
    Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study.
    Varenna M, Zucchi F, Ghiringhelli D, Binelli L, Bevilacqua M, Bettica P, Sinigaglia L.
    J Rheumatol; 2000 Jun; 27(6):1477-83. PubMed ID: 10852274
    [Abstract] [Full Text] [Related]

  • 5. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE.
    J Natl Cancer Inst; 2005 Jan 05; 97(1):59-69. PubMed ID: 15632381
    [Abstract] [Full Text] [Related]

  • 6. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC, Papapoulos SE, Gelderblom H, Seynaeve C, den Hartigh J, Vermeij P, van der Rijt CC, van Zuylen L.
    J Bone Miner Res; 2005 Sep 05; 20(9):1543-7. PubMed ID: 16059626
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
    Kylmälä T, Tammela TL, Lindholm TS, Seppänen J.
    Ann Chir Gynaecol; 1994 Sep 05; 83(4):316-9. PubMed ID: 7537482
    [Abstract] [Full Text] [Related]

  • 10. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M, Takahashi S, Ogata E.
    Anticancer Res; 2003 Sep 05; 23(5b):4095-9. PubMed ID: 14666607
    [Abstract] [Full Text] [Related]

  • 11. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
    Generali D, Berruti A, Tampellini M, Dovio A, Tedoldi S, Bonardi S, Tucci M, Allevi G, Aguggini S, Milani M, Bottini A, Dogliotti L, Angeli A.
    Bone; 2007 Jan 05; 40(1):182-8. PubMed ID: 16935041
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
    Piga A, Bracci R, Ferretti B, Sandri P, Nortilli R, Acito L, Pancotti A, Di Furia L, Carle F, Cellerino R.
    J Exp Clin Cancer Res; 1998 Jun 05; 17(2):213-7. PubMed ID: 9700583
    [Abstract] [Full Text] [Related]

  • 14. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.
    Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, Torta M, Porpiglia F, Fontana D, Angeli A.
    J Urol; 2000 Oct 05; 164(4):1248-53. PubMed ID: 10992374
    [Abstract] [Full Text] [Related]

  • 15. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J.
    Rheumatology (Oxford); 2004 Jul 05; 43(7):869-74. PubMed ID: 15054158
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Polascik TJ, Given RW, Metzger C, Julian SR, Vestal JC, Karlin GS, Barkley CS, Bilhartz DL, McWhorter LT, Lacerna LV.
    Urology; 2005 Nov 05; 66(5):1054-9. PubMed ID: 16286123
    [Abstract] [Full Text] [Related]

  • 18. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y, Ochi M, Tokue A.
    Hinyokika Kiyo; 2000 Dec 05; 46(12):869-72. PubMed ID: 11211802
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.
    O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA.
    J Clin Oncol; 1995 Apr 05; 13(4):929-34. PubMed ID: 7707121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.